Frequent early multiple sclerosis relapses during treatment with fingolimod: A paradoxical effect?

Multiple Sclerosis Journal

Volumn 19, Issue 11, 2013, Pages 1550-

  Ferraro, D ^a   Federzoni, L ^a   Vitetta, F ^a   Simone, A M ^a   Cossarizza, A ^a   Nichelli, P F ^a   Sola, P ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GLATIRAMER; INTERLEUKIN 2; NATALIZUMAB;

BRAIN DAMAGE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG SUBSTITUTION; HUMAN; LETTER; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REGULATORY T LYMPHOCYTE; RELAPSE;

BRAIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; NEUROMYELITIS OPTICA; PROPYLENE GLYCOLS; SPHINGOSINE;

EID: 84884542080     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513490549     Document Type: Letter

References (5)

1. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler. 2012 ; 18: 113-115
2. Daelman L, Maitrot A, Maarouf A, et al. Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler. 2012 ; 18: 1647-1649
3. Rinaldi F, Seppi D, Calabrese M, et al. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: Clinical and magnetic resonance imaging findings. Mult Scler. 2012 ; 18: 1640-1643
4. Wolf AM, Eller K, Zeiser R, et al. The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo. J Immunol. 2009 ; 183: 3751-3760
5. Sawicka E, Dubois G, Jarai G, et al. The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. Journ Immunol. 2005 ; 175: 7973-7980